Skip to main content
. 2019 Aug 29;105(4):925–936. doi: 10.3324/haematol.2018.210286

Figure 6.

Figure 6.

The ARHGEF12-RhoA-p38 pathway is associated with erythroid regeneration from chemotherapy-induced anemia in acute lymphoblastic leukemia (ALL) patients. (A) Erythroid differentiation evaluation by flow cytometry of cryopreserved bone marrow (BM) samples from patients in remission with different rs10892563 genotypes. Three populations of different development stages, i.e. CD71+CD235a- pro-erythroblasts (Pro-E), CD71+CD235a+ erythroblasts and CD71CD235a+ erythrocytes can be discriminated. Representative flow cytometry dot plots showing the percentage of erythroblasts in patients with CC genotype was higher than TT genotype, whereas the pro-erythroblasts (Pro-E) and erythrocytes were reduced in CC genotype. (B) The TT group and the CC group each had nine samples. Proportion statistics of each stage of erythroid differentiation are shown. (C) Statistics of mean fluorescence intensity of phospho-p38. We compared the base-2 log of phos-pho-p38 levels between the CC and TT genotypes, phospho-p38 levels are lower in the CC genotype patients (P=0.0471, one-tailed t-test). (D) Phospho-flow histograms of phospho-p38 on pro-erythroblasts with different rs10892563 genotypes. Phosphorylated p38 was stained with anti-pT180/pY182 antibody on cryopreserved BM samples from patients in remission with different rs10892563 genotypes as well as CD71 and CD235a monoclonal antibody. Histograms showing phospho-p38 peaks shifted left in CC genotype (black) comparing TT genotype (gray).